Drug intelligence / Profile preview

TBR571R

Development stage: Preclinical
Lead developer: Twinpig Biolab
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

TBR571R is a preclinical theranostic peptide-drug conjugate (PDC) developed by TwinPigBio, designed to target Fibroblast Activation Protein (FAP) on Cancer-Associated Fibroblasts (CAFs). Built on the company's proprietary TAMpep™ - ESCLink™ platform, it incorporates a Lutetium-177 (177Lu) radioisotope payload. This theranostic approach allows for both high-resolution imaging of the tumor stroma and targeted delivery of ionizing radiation to treat various cancers by disrupting the tumor-supportive microenvironment.

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on TBR571R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBR571R.

Explore the full profile